Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cognition Therapeutics ( (CGTX) ) is now available.
On June 18, 2025, Cognition Therapeutics, Inc. conducted its Annual Meeting of Stockholders virtually. During the meeting, Peggy Wallace and Ellen B. Richstone were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2025 fiscal year. These decisions are expected to impact the company’s governance and financial oversight positively.
The most recent analyst rating on (CGTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.
Spark’s Take on CGTX Stock
According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.
Cognition Therapeutics is currently facing major financial challenges with persistent losses and cash flow issues. Technical indicators provide mixed signals with short-term momentum but long-term caution. Valuation remains a concern with negative earnings and no dividend yield. Although the earnings call highlighted some strategic progress, significant concerns like NASDAQ compliance and uncertain funding overshadow these advancements. Overall, the stock is a high-risk investment with potential for future improvement if financial and strategic objectives are met.
To see Spark’s full report on CGTX stock, click here.
More about Cognition Therapeutics
Cognition Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for neurodegenerative diseases.
Average Trading Volume: 1,096,660
Technical Sentiment Signal: Sell
Current Market Cap: $17.36M
For detailed information about CGTX stock, go to TipRanks’ Stock Analysis page.